Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects \>/= 18 years of age
Life expectancy of at least 3 months
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Subjects with metastatic colorectal cancer (Stage IV)
Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS mutation)
Eastern Cooperative Oncology Group (ECOG) Performance Status of \</= 1
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements
Women of childbearing potential and men must agree to use adequate contraception since signing of the inform consent (IC) form until at least 3 months after the last study drug administration
You may not be if
Prior treatment with regorafenib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug
Pregnant or breast-feeding subjects
Congestive heart failure \>/= New York Heart Association (NYHA) class 2
Myocardial infarction less than 6 months before start of study drug
Ongoing infection \> Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0
